Bosentan

Concomitant administration of glyburide and bosentan is contraindicated due to increased risk of liver enzyme elevations.

Concomitant administration is contraindicated due to increased risk of liver enzyme elevations.

Concomitant administration is contraindicated due to increased risk of liver enzyme elevations.

Moderate CYP3A inducer that decreases lemborexant exposure, which may reduce DAYVIGO efficacy. Concomitant use should be avoided.

As a CYP2C9 inhibitor, amiodarone combined with a strong or moderate CYP3A inhibitor will likely lead to large increases in bosentan plasma concentrations.

Moderate CYP3A inhibitor; when combined with a CYP2C9 inhibitor, will likely lead to large increases in bosentan plasma concentrations. Co-administration not recommended.

Moderate CYP3A inhibitor; when combined with a CYP2C9 inhibitor, will likely lead to large increases in bosentan plasma concentrations. Co-administration not recommended.

Moderate CYP3A inhibitor; when combined with a CYP2C9 inhibitor, will likely lead to large increases in bosentan plasma concentrations. Co-administration not recommended.

Bosentan decreases ethinyl estradiol exposure by average of 31%, with decreases up to 66% in individual subjects, reducing hormonal contraceptive effectiveness.

As a CYP2C9 inhibitor, fluconazole combined with a strong or moderate CYP3A inhibitor will likely lead to large increases in bosentan plasma concentrations.

Strong CYP3A inhibitor; when combined with a CYP2C9 inhibitor, will likely lead to large increases in bosentan plasma concentrations. Co-administration not recommended.

Strong CYP3A inhibitor; when combined with a CYP2C9 inhibitor, will likely lead to large increases in bosentan plasma concentrations. Co-administration not recommended.

Moderate CYP3A4 inducer decreases lurasidone exposure. Lurasidone dose should be increased.

Strong CYP3A4 inducer may reduce plasma macimorelin concentrations and lead to false positive test results. Discontinue prior to use.

Moderate CYP3A inducer may decrease medroxyprogesterone acetate concentrations and reduce contraceptive efficacy. Avoid concomitant use or use backup contraception.

Bosentan decreases norethindrone exposure by average of 14%, with decreases up to 56% in individual subjects, reducing hormonal contraceptive effectiveness.

May decrease contraceptive effectiveness and increase breakthrough bleeding through CYP3A4 induction.

May decrease plasma concentrations of COCs and potentially diminish effectiveness or increase breakthrough bleeding.

Bosentan reduces effectiveness of oral, injectable, transdermal, and implantable hormonal contraceptives by decreasing exposure to ethinyl estradiol (31% average, up to 66%) and norethindrone (14% average, up to 56%).

CYP2C9 inducer that decreases warfarin exposure and INR; requires close INR monitoring.

CYP2C9 inducer that decreases warfarin effect and INR; requires closer INR monitoring.

Moderate CYP3A4/5 inducer may reduce axitinib plasma exposure and should be avoided if possible.

Decreases cyclosporine concentrations; appropriate dosage adjustment required.

Induces CYP3A4 and may decrease plasma concentrations of desogestrel and ethinyl estradiol, potentially diminishing contraceptive effectiveness and increasing breakthrough bleeding.

May decrease systemic concentrations of hormonal contraceptives and diminish effectiveness or increase breakthrough bleeding.

Induces CYP3A4 enzyme, may decrease effectiveness of COCs or increase breakthrough bleeding.

May decrease the effectiveness of hormonal contraceptives or increase breakthrough bleeding through CYP3A4 enzyme induction.

Enzyme inducer that may decrease effectiveness of COCs or increase breakthrough bleeding. Use back-up contraception.

OATP1B1 substrate; eltrombopag may increase exposure. Monitor closely and consider dose reduction if appropriate.

OATP1B1 substrate; monitor for excessive exposure and consider dose reduction if appropriate.

CYP3A4 enzyme inducer that may decrease the effectiveness of the contraceptive or increase breakthrough bleeding.

May decrease plasma concentrations of etonogestrel and diminish contraceptive effectiveness or increase breakthrough bleeding.

CYP3A4 enzyme inducer that may decrease plasma concentrations of etonogestrel and ethinyl estradiol, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.

Induces CYP3A4, may decrease plasma concentrations of CHCs and potentially diminish effectiveness or increase breakthrough bleeding.

OATP1B1 substrate; gemfibrozil inhibition may increase bosentan exposure, requiring dosing reduction.

Bosentan induces CYP3A4 and may decrease plasma concentrations of COCs, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.

Bosentan induces CYP3A4 enzymes, potentially decreasing contraceptive effectiveness and increasing breakthrough bleeding.

Enzyme inducer that may decrease plasma concentrations of contraceptive hormones and reduce effectiveness of hormonal contraceptives or increase breakthrough bleeding.

Enzyme inducer that may decrease plasma concentrations of CHCs and potentially diminish effectiveness or increase breakthrough bleeding.

CYP3A4 inducer that may decrease the effectiveness of COCs or increase breakthrough bleeding.

Enzyme inducer that may decrease plasma concentrations of norethindrone and ethinyl estradiol, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.

May decrease plasma concentrations and efficacy of contraceptive; may increase breakthrough bleeding.

Metabolic enzyme inducer that may decrease systemic concentrations of estrogen and/or progestin, potentially diminishing contraceptive effectiveness.

Concomitant use decreases sildenafil exposure. Dose up-titration of sildenafil may be needed when initiating treatment.

Bosentan decreases sildenafil exposure; dose up-titration of sildenafil may be needed when initiating treatment.

CYP3A4 inducer decreases plasma concentrations of ulipristal acetate and may decrease its effectiveness as emergency contraception.